ConductScience.org, home

Paper6437469

Progress in gall stone disease.

Bateson MC. Br Med J (Clin Res Ed), 1984. Cited by 3 papers, by iCite.

Cite this record

ConductScience Library. Progress in gall stone disease. Papers, record 6437469. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6437469

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Progress in gall stone disease.
PubMed
Journal
Br Med J (Clin Res Ed)
PubMed
Year
1984
PubMed
Publication types
Editorial
PubMed
Citations, by iCite
3
iCite
Relative citation ratio, by iCite
0.26
iCite
Revised in PubMed
2019-05-01
PubMed

Authors1

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bateson MCM C

Source PubMed

Download CSV of authors

Topics6

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
CholelithiasisMajor topic
Female
Humans
Male
Ultrasonography
Ursodeoxycholic Acid

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1685927Clofibrate therapy and gallstone induction.Am J Dig Dis1978https://conductscience.org/library/papers/685927PubMed
27380174Monooctanoin, a dissolution agent for retained cholesterol bile duct stones: physical properties and clinical application.Gastroenterology1980https://conductscience.org/library/papers/7380174PubMed
36109120Intraductal infusion of mono-octanoin: experience in 24 patients with retained common-duct stones.Lancet1981https://conductscience.org/library/papers/6109120PubMed
47053334Estrogen predisposes to cholecystectomy but not to stones.Gastroenterology1982https://conductscience.org/library/papers/7053334PubMed
56119557Is recurrence inevitable after gallstone dissolution by bile-acid treatment?Lancet1982https://conductscience.org/library/papers/6119557PubMed
67060825Gallstone dissolution after 6 months of ursodeoxycholic acid (UDCA): effectiveness of different doses.J Int Med Res1982https://conductscience.org/library/papers/7060825PubMed
76803946Gall-stone dissolution and recurrence: are we being misled?Br Med J (Clin Res Ed)1982https://conductscience.org/library/papers/6803946PubMed
87110244The natural history of silent gallstones: the innocent gallstone is not a myth.N Engl J Med1982https://conductscience.org/library/papers/7110244PubMed
97051912Ursodeoxycholic acid: a safe and effective agent for dissolving cholesterol gallstones.Ann Intern Med1982https://conductscience.org/library/papers/7051912PubMed
107140487Gallstone dissolution rate during chenic acid therapy. Effect of bedtime administration plus low cholesterol diet.Dig Dis Sci1982https://conductscience.org/library/papers/7140487PubMed
117141392Ursodeoxycholic acid vs. chenodeoxycholic acid as cholesterol gallstone-dissolving agents: a comparative randomized study.Hepatology1982https://conductscience.org/library/papers/7141392PubMed
126345281Medical treatment of biliary duct stones: effect of ursodeoxycholic acid administration.Gut1983https://conductscience.org/library/papers/6345281PubMed
136873581[Recurrence and prevention of recurrence after dissolution of gallbladder lithiasis by chenodeoxycholic acid in 22 patients].Gastroenterol Clin Biol1983https://conductscience.org/library/papers/6873581PubMed
146881778Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival.Ann Intern Med1983https://conductscience.org/library/papers/6881778PubMed
156884818Nucleation of cholesterol monohydrate crystals from hepatic and gall-bladder bile of patients with cholesterol gall stones.Gut1983https://conductscience.org/library/papers/6884818PubMed
166690352Supersaturated bile from obese patients without gallstones supports cholesterol crystal growth but not nucleation.Gastroenterology1984https://conductscience.org/library/papers/6690352PubMed
176364909Low-dose chenodiol to prevent gallstone recurrence after dissolution therapy.Ann Intern Med1984https://conductscience.org/library/papers/6364909PubMed
186364910Additional chenodiol therapy after partial dissolution of gallstones with two years of treatment.Ann Intern Med1984https://conductscience.org/library/papers/6364910PubMed
196671484Ursodeoxycholic acid for the dissolution of radiolucent gall bladder stones.Digestion1983https://conductscience.org/library/papers/6671484PubMed
206706305Franco-Belgian cooperative study of ursodeoxycholic acid in the medical dissolution of gallstones: a double-blind, randomized, dose-response study, and comparison with chenodeoxycholic acid.Hepatology1984https://conductscience.org/library/papers/6706305PubMed

See all 22 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.

PMIDTitleJournalYearIn Papers
3906614Review of general surgery 1984-85.Postgrad Med J1985https://conductscience.org/library/papers/3906614

Source PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/6437469

GET https://conductscience.org/api/papers/v1/6437469/references?page=2